Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole

To characterise the effects of itraconazole, a potent inhibitor of CYP3A4, on the pharmacokinetics of selegiline in healthy volunteers. In this randomised, placebo-controlled crossover study with two phases, 12 healthy volunteers took either 200 mg itraconazole or matched placebo once daily for 4 da...

Ausführliche Beschreibung